Innate Pharma (IPHA) Accumulated Depreciation & Amortization (2020 - 2025)
Historic Accumulated Depreciation & Amortization for Innate Pharma (IPHA) over the last 6 years, with Q2 2025 value amounting to -$800295.4.
- Innate Pharma's Accumulated Depreciation & Amortization rose 3515.22% to -$800295.4 in Q2 2025 from the same period last year, while for Jun 2025 it was -$800295.4, marking a year-over-year increase of 3515.22%. This contributed to the annual value of $1.3 million for FY2024, which is N/A changed from last year.
- According to the latest figures from Q2 2025, Innate Pharma's Accumulated Depreciation & Amortization is -$800295.4, which was up 3515.22% from $2.1 million recorded in Q4 2024.
- Over the past 5 years, Innate Pharma's Accumulated Depreciation & Amortization peaked at $46.3 million during Q4 2022, and registered a low of -$4.0 million during Q2 2023.
- Over the past 5 years, Innate Pharma's median Accumulated Depreciation & Amortization value was -$800295.4 (recorded in 2025), while the average stood at $5.4 million.
- Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first tumbled by 9223.6% in 2021, then skyrocketed by 78107.74% in 2022.
- Over the past 5 years, Innate Pharma's Accumulated Depreciation & Amortization (Quarter) stood at $5.3 million in 2021, then surged by 781.08% to $46.3 million in 2022, then crashed by 88.18% to $5.5 million in 2023, then plummeted by 61.1% to $2.1 million in 2024, then tumbled by 137.56% to -$800295.4 in 2025.
- Its Accumulated Depreciation & Amortization was -$800295.4 in Q2 2025, compared to $2.1 million in Q4 2024 and -$1.2 million in Q2 2024.